Zdrowie i gospodarka · 13/08/2020

FDA Drafts Guidance for Industry on AML Treatment Development

The Food and Drug Administration (FDA) has released a draft guidance for industry on developing drugs and biological products for treating acute myeloid leukemia (AML). The guidance aims to assist sponsors in the clinical development of AML treatments, covering topics such as drug development, efficacy endpoints, and trial considerations.